BioSpace News Archive

Gritstone bio, Inc. announced that the company’s Board of Directors granted three employees nonqualified stock options to purchase an aggregate of 12,400 shares of its common stock with an exercise price of $3.59, which is equal to the closing price of Gritstone’s common stock on September 9, 2022, the last trading day preceding the grant date of the awards.

The board of Current Biologics has selected Tom Hochuli as chief executive officer of the startup company, which is focused on providing cell and gene therapy manufacturing and development services to the biotechnology and pharmaceutical industries.

Zimmer Biomet Holdings, Inc. today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Identity™ Shoulder System for anatomic, reverse and revision shoulder replacement.

Prelude Corporation today announced the publication of clinical study data in the International Journal of Radiation Oncology· Biology· Physics (“Red Journal”).

Octagon Therapeutics today announced the initiation of a research collaboration with Novo Nordisk focused on inflammatory disease.

NorthStar Medical Radioisotopes, LLC and IBA announced a new agreement under which NorthStar will purchase two additional Rhodotron® TT300 HE electron beam accelerators, and the associated beamlines, from IBA for the production of molybdenum-99.

Sonendo ® Sponsors Inaugural Women in Endodontics Summit.

Scholar Rock today announced that its Board of Directors appointed Jay Backstrom, M.D., M.P.H., as Chief Executive Officer-Elect, effective September 20, 2022.

BridgeBio Pharma, Inc. and Sentynl Therapeutics, Inc. today announced the European Commission (EC) has granted marketing authorization for NULIBRY® (fosdenopterin) for Injection as the first therapy for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A.

Generation Bio Co. announced the promotion of Phillip Samayoa, Ph.D., to chief strategy officer.